Utama › Kanser Endometrium › Texas › San Antonio
Kajian klinikal Kanser Endometrium di San Antonio, TX
27 kajian untuk Kanser Endometrium sedang mencari peserta di lokasi dalam dan sekitar San Antonio (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of PHST001 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- START Center for Cancer Research - San Antonio, San Antonio
- University of Texas (UT) Health, San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Mengambil pesertaFasa 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Mengambil pesertaFasa 3
- Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Mengambil pesertaFasa 1/2
- START Center for Cancer Research, San Antonio
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Mengambil pesertaKajian pemerhatian
- The University of Texas Health Science Center at San Antonio, San Antonio
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Mengambil pesertaFasa 1
- START - San Antonio, San Antonio
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Mengambil pesertaFasa 3
- USOR - TX Oncology - SA NE, San Antonio
- NEXT San Antonio, San Antonio
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Mengambil pesertaFasa 3
- Research Site, San Antonio
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Mengambil pesertaFasa 1
- NEXT San Antonio, San Antonio
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Mengambil pesertaFasa 1
- Normunity Investigational Site, San Antonio
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- UT Health Mays Cancer Center, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1
- START - San Antonio, San Antonio
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Texas Oncology - San Antonio, San Antonio
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Mengambil pesertaFasa 3
- Texas Oncology San Antonio Medical Center, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Mengambil pesertaFasa 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Mengambil pesertaFasa 1
- NEXT San Antonio, San Antonio
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- START San Antonio, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Mengambil pesertaFasa 1
- NEXT Oncology, San Antonio
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- START, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Mengambil pesertaFasa 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 2
- START San Antonio, San Antonio
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- NEXT Oncology, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Mengambil pesertaFasa 1
- Dren Investigational Site, San Antonio
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Mengambil pesertaFasa 2/3
- Texas Oncology-San Antonio Medical Center, San Antonio
Kajian Kanser Endometrium di bandar lain
- Houston, TX68 kajian
- New York City, NY52 kajian
- Boston, MA50 kajian
- Arlington, VA39 kajian
- Nashville, TN38 kajian
- Los Angeles, CA34 kajian
- St. Louis, MO29 kajian
- Philadelphia, PA28 kajian
- Columbus, OH25 kajian
- Oklahoma City, OK25 kajian
- Chicago, IL25 kajian
- Queens, NY25 kajian
Kajian lain di San Antonio
- Kanser Paru-paru Bukan Sel Kecil59 kajian
- Kanser Payudara47 kajian
- Kanser Kolorektal46 kajian
- Kanser Metastatik44 kajian
- Kanser (semua jenis)41 kajian
- Obesiti40 kajian
- Diabetes Jenis 237 kajian
- Berat Badan Berlebihan34 kajian
- Kanser Ovari31 kajian
- Kanser Pankreas31 kajian
- Kanser Prostat28 kajian
- Kanser Paru-paru26 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.